Aclaris Therapeutics (ACRS) Financials: History & Chart

Aclaris Therapeutics, Inc.(ACRS)

Biotechnology · Wayne, PA

$3.70-0.57 (-13.35%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Wayne, PA

71 employees

www.aclaristx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neal S. Walker

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	8.22M	1.63M	2.00M	1.29M	3.30M	1.78M	1.46M	9.21M	4.35M
Cost of Goods Sold	361K	231K	395K	-803K	538K	1.85M	506K	9.30M	2.41M
Gross Profit	7.86M	1.40M	1.60M	2.10M	2.76M	-73K	949K	-90K	1.94M
Gross Profit Margin	95.6%	85.8%	80.2%	162.0%	83.7%	-4.1%	65.2%	-1.0%	44.6%
Total Operating Expenses	94.17M	25.64M	23.79M	24.83M	19.91M	18.34M	19.03M	99.58M	12.41M
Research & Development	64.12M	18.85M	15.66M	16.58M	13.03M	11.45M	11.58M	9.03M	5.96M
Selling, General & Administrative	23.24M	6.05M	6.74M	5.58M	4.87M	5.39M	6.14M	4.95M	5.65M
Operating Income (EBIT)	-86.31M	-24.24M	-22.19M	-22.73M	-17.15M	-18.41M	-18.08M	-99.67M	-10.47M
Operating Margin	-1050.2%	-1487.9%	-1111.8%	-1755.5%	-519.8%	-1035.9%	-1242.9%	-1082.1%	-240.9%
Income Before Tax (EBT)	-75.74M	-21.50M	-19.82M	-19.80M	-14.61M	-15.43M	-15.09M	-96.55M	-7.59M
Interest Income	6.73M	1.76M	1.51M	1.63M	1.82M	2.02M	2.17M	2.10M	1.99M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	10.57M	2.73M	2.37M	2.94M	2.54M	2.98M	3.00M	3.12M	2.88M
Net Income	-75.74M	-21.50M	-19.82M	-19.80M	-14.61M	-15.43M	-15.09M	-96.55M	-7.59M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-921.5%	-1320.1%	-993.2%	-1528.6%	-443.0%	-868.3%	-1036.8%	-1048.2%	-174.6%
EBITDA	-85.69M	-24.03M	-22.09M	-22.63M	-16.94M	-18.29M	-17.96M	-99.53M	-10.29M
EBITDA Margin	-1042.6%	-1475.1%	-1106.7%	-1747.6%	-513.5%	-1029.5%	-1234.1%	-1080.6%	-236.8%
Depreciation & Amortization	623K	209K	102K	102K	210K	114K	128K	143K	179K
EPS Basic	-0.58	-0.15	-0.15	-0.16	-0.12	-0.13	-0.12	-1.01	-0.11
EPS Diluted	-0.58	-0.15	-0.15	-0.16	-0.12	-0.13	-0.12	-1.01	-0.11
Weighted Average Basic Shares	142.74M	142.74M	128.81M	122.66M	122.62M	122.58M	122.39M	95.31M	71.38M
Weighted Average Diluted Shares	142.74M	142.74M	128.81M	122.66M	122.62M	122.58M	122.39M	95.31M	71.38M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	7.83M	18.72M	31.25M	29.75M	6.76M	6.48M	4.23M	10.09M
Cost of Goods Sold	2.09M	2.79M	18.08M	11.96M	4.71M	5.13M	4.05M	6.85M
Gross Profit	5.74M	15.93M	13.17M	17.79M	2.05M	1.35M	172K	3.24M
Gross Profit Margin	73.3%	85.1%	42.1%	59.8%	30.3%	20.8%	4.1%	32.1%
Total Operating Expenses	82.11M	157.86M	110.53M	107.65M	91.77M	52.26M	92.73M	138.66M
Research & Development	52.65M	33.59M	98.38M	77.81M	43.81M	29.34M	64.90M	63.01M
Selling, General & Administrative	21.97M	22.20M	31.10M	25.13M	23.62M	20.53M	27.83M	75.65M
Operating Income (EBIT)	-76.38M	-141.93M	-97.36M	-89.85M	-89.72M	-50.91M	-111.06M	-135.41M
Operating Margin	-975.9%	-758.2%	-311.6%	-302.0%	-1327.1%	-785.4%	-2627.3%	-1341.9%
Income Before Tax (EBT)	-64.92M	-132.06M	-88.85M	-86.91M	-90.86M	-51.34M	-113.54M	-132.74M
Interest Income	7.64M	7.95M	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	11.45M	9.87M	8.51M	2.95M	-1.14M	-424K	-2.48M	2.68M
Net Income	-64.92M	-132.06M	-88.48M	-86.91M	-90.86M	-51.02M	-161.35M	-132.74M
Income Tax Expense	0.00	0.00	-367K	0.00	0.00	-182K	0.00	2.68M
Net Profit Margin	-829.6%	-705.5%	-283.1%	-292.1%	-1344.0%	-787.0%	-3817.2%	-1315.4%
EBITDA	-75.92M	-141.13M	-96.49M	-89.06M	-88.80M	-49.59M	-109.47M	-134.09M
EBITDA Margin	-970.1%	-753.9%	-308.8%	-299.3%	-1313.4%	-765.0%	-2589.8%	-1328.8%
Depreciation & Amortization	454K	807K	863K	797K	923K	1.32M	1.59M	1.32M
EPS Basic	-0.53	-1.71	-1.27	-1.33	-1.60	-1.20	-3.46	-4.03
EPS Diluted	-0.53	-1.71	-1.27	-1.33	-1.60	-1.20	-3.46	-4.03
Weighted Average Basic Shares	122.66M	77.30M	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M
Weighted Average Diluted Shares	122.66M	77.30M	69.81M	65.21M	56.73M	42.54M	41.32M	32.91M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.